A Phase II Clinical Trial of a Randomized, Double-Blind, Placebo Controlled Clinical Trial of DFMO [eflornithine] and Sulindac Against Various Endpoints of Colorectal Pathobiology in a Cohort of Individuals at Increased Risk of Colorectal Carcinoma
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2015
At a glance
- Drugs Eflornithine (Primary) ; Sulindac (Primary)
- Indications Colorectal cancer
- Focus Biomarker; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 14 Mar 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 14 Mar 2012 Actual patient number (324) added as reported by ClinicalTrials.gov.